Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
In 2004, Pfizer agreed to pay $430 million in a DOJ settlement and pleaded guilty to two violations of the Food, Drug and Cosmetic Act for marketing the drug Neurontin, also known as gabapentin Federal prosecutors on Thursday announced that Pfizer has agreed to plead guilty to criminal wrongdoing and pay a settlement of $430 million in a whistleblower lawsuit alleging that the Parke-Davis unit of Pfizer subsidiary Warner-Lambert illegally encouraged physicians to prescribe the epilepsy drug Neurontin to treat conditions other than those approved by FDA, USA Today reports. The manufacturers of the drug Neurontin reached a $325 million class action lawsuit settlement Wednesday over allegations they fraudulently marketed the prescription drug, which is used to treat seizures, restless leg syndrome, and pain caused by shingles. If approved, third-party payers of the drug will be eligible to claim a cash award from the Neurontin class action settlement, announced Pfizer Inc <PFE.N> violated federal racketeering law by improperly promoting the epilepsy drug Neurontin, a Boston jury found on Thursday, and the world's largest drugmaker was ordered to (SACRAMENTO) – Attorney General Bill Lockyer today announced a $430 million settlement with Pfizer, Inc. and subsidiary Warner-Lambert to resolve state and federal allegations of deceptive marketing, Medicaid fraud and illegal kickbacks in Warner-Lambert's promotion and sale of the epilepsy drug Neurontin. "Drug companies' profits should not come at the expense of patient safety and the Recently, lawsuits alleging damages from illegal marketing of another old drug, gabapentin (Neurontin), have yielded remarkable discoveries about the structure and function of pharmaceutical The recent news on Neurontin is a case in point. Neurontin, manufactured by Pfizer and Parke-Davis, is the brand name for the drug gabapentin. It is approved to treat epilepsy and post-herpetic neuralgia but may also be used off-label, i.e., for uses not approved by the Food and Drug Administration (FDA). By Lawrence Hurley WASHINGTON (Reuters) - The U.S. Supreme Court on Monday left intact a $142 million jury verdict against Pfizer Inc over the marketing of the epilepsy drug Neurontin. In 2010 Here's who gabapentin was originally approved for, what it's used for today and why it's becoming a drug of increasing concern for abuse and misuse. Pfizer, the world's largest drug maker, pleaded guilty on 13 May to numerous civil and criminal charges for illegally promoting the off-label use of gabapentin (Neurontin). It has agreed to pay a $240m (£136m; €200m) criminal fine and $152m to state and federal healthcare programmes. The fine is the second largest given in the industry. Meanwhile, off-label sales of gabapentin continue to It’s fast becoming the go-to drug for addicts in search of a stronger high — and it is not even an opioid. Gabapentin, a purportedly nonaddictive painkiller primarily used to treat shingles The lawsuit alleged that while Neurontin was approved only as an epilepsy drug, the company promoted it for relieving pain, headaches, bipolar disorder and other psychiatric illnesses. A federal appeals court has upheld a $142 million jury verdict in a case involving Pfizer's epilepsy drug Neurontin, and opened the door for potentially The settlement includes $152 million to pay back amounts spent on Neurontin by the federal Medicare program and 50 state Medicaid programs for the poor. In addition, Pfizer will pay a $240 million Recently, lawsuits alleging damages from illegal marketing of another old drug, gabapentin (Neurontin), have yielded remarkable discoveries about the structure and function of pharmaceutical A $190 million settlement has been reached in New York in a consumer fraud class action lawsuit pending against Pfizer which alleges the pharma giant engaged in tactics to delay market entry of generic versions of its epilepsy drug Neurontin. The lawsuit was filed by purchasers of Neurontin in 2002, claiming Pfizer Neurontin. Serving as co-lead counsel, Garwin Gerstein & Fisher LLP achieved a $190 million recovery for the Direct Purchaser Class. We would like to show you a description here but the site won’t allow us. Pfizer Admits Guilt in Promotion of Neurontin--Agrees to Pay $430 Million Sun, 16 May 2004 A lawsuit initiated by Dr. David Franklin, a whistleblower, has been settled: Pfizer pleaded guilty to criminal fraud in the promotion of Neurontin, and agreed to pay $430 million. This case is but an example of contemporary drug marketing, demonstrating The drug Neurontin was approved by the Food and Drug Administration in December 1993 solely for adjunctive or supplemental anti-seizure use by epilepsy patients. Under the provisions of the Food, Drug and Cosmetic Act, a company must specify the intended uses of a product in its new drug application to FDA.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |